Lynx Dx

11/06/2025

MyProstateScore 2.0 (MPS2) works in conjunction with PSA testing and traditional risk calculators, providing patients and providers with best-in-class accuracy.

And with MPS2, patients can forgo the discomfort of a DRE and screen for prostate cancer in the comfort of their home.

Read more about MPS2’s clinical validation in the Journal of Urology: https://www.lynxdx.com/2025/01/clinical-research-publications/mps2-clinical-validation-non-dre-urine/

11/01/2025

We’re headed to Napa, CA this weekend for the Western Section of the American Urological Association, happening November 2-6!

Come meet the Lynx Dx team and learn how MyProstateScore 2.0 (MPS2) is changing the way we think about prostate cancer risk. No DRE, just accurate, actionable insights.

We’ll share how MPS2 helps guide biopsy decisions, works hand-in-hand with PSA, and integrates smoothly into your practice.

Let’s start the conversation about smarter screening and better patient care.

Learn more: https://www.lynxdx.com/my-prostate-score/providers/

10/24/2025

We’re proud to recognize the work of Dr. Arul Chinnaiyan, Lynx Dx's Co-Founder, and his colleagues at the University of Michigan, whose latest research uncovers a targeted strategy to inhibit prostate cancer growth through precision protein degradation.

This discovery reflects the same commitment to evidence-based innovation that led to the development of Lynx Dx's MyProstateScore 2.0 (MPS2), our next-gen, noninvasive test for prostate cancer risk assessment.

Read more about Dr. Chinnaiyan's research here: https://goodmenproject.com/featured-content/researchers-find-a-targeted-approach-to-shut-down-prostate-cancer-growth/

Study shows a novel compound that degrades key proteins found in prostate cancer cells blocks oncogenic androgen receptor signaling

10/23/2025

Too many men put off prostate cancer screening.

At Lynx Dx, we’ve made screening for prostate cancer easy and stress-free. MyProstateScore 2.0 (MPS2) is a urine-based, noninvasive test that can be completed at-home or in-office.

Learn more here: https://www.LynxDx.com/my-prostate-score/providers/

10/01/2025

We’re on the road this October!

Come meet the Lynx Dx team and learn how MyProstateScore 2.0 (MPS2) is changing the way we think about prostate cancer risk. No DRE, just accurate, actionable insights.

We’ll share how MPS2 helps guide biopsy decisions, works hand-in-hand with PSA, and integrates smoothly into your practice.

Let’s start the conversation about smarter screening and better patient care.

https://bit.ly/430RWop

09/30/2025

Come connect with our Director of Research and Development Dr. Jacob Meyers at this year’s Tech Homecoming in our hometown of Ann Arbor, Michigan!

Register today: https://a2spark.org/TH25

We look forward to meeting you!

09/26/2025

Congratulations to ExoDx Prostate Test and mdxhealth on their acquisition announcement. Partnerships like this mean one thing: better outcomes for patients.

At Lynx Dx, we're proud to be part of an industry dedicated to transforming patient care through accurate, accessible testing. We remain dedicated to advancing prostate cancer care with our MyProstateScore 2.0 (MPS2) test, providing urologists and patients with best-in-class accuracy and data-driven insights for confident decisions.

Together, we're building a future where every patient receives the right care at the right time.

09/05/2025

September is Prostate Cancer Awareness Month, a time to start conversations, share knowledge, and encourage proactive health discussions. Prostate cancer is one of the most common cancers in men, but when caught early, it’s often treatable.

At Lynx Dx, we’re committed to making screening less stressful and more accessible. Our urine-based test, MyProstateScore 2.0 (MPS2), was designed to help men and their doctors better understand prostate cancer risk, without discomfort. And now, you can even collect your sample at home.

Learn more about MyProstateScore 2.0 (MPS2) here: https://www.lynxdx.com/

Awareness starts with action. If you or someone you love is due for screening, talk to your healthcare provider and learn what options are available. Every conversation matters.

09/03/2025

We’re on the road this September!

Come meet the Lynx Dx team and learn how MyProstateScore 2.0 (MPS2) is changing the way we think about prostate cancer risk. No DRE, just accurate, actionable insights.

We’ll share how MPS2 helps guide biopsy decisions, works hand-in-hand with PSA, and integrates smoothly into your practice.

Let’s start the conversation about smarter screening and better patient care.

https://bit.ly/44HZL30

07/22/2025

What does the research really say about diet and prostate cancer risk?

While the evidence is still evolving, studies continue to explore how dietary factors like lycopene, phytochemicals, and fatty acids may influence prostate cancer risk. This blog outlines both well-established insights (e.g., the benefits of plant-based antioxidants) and areas of active investigation helping providers stay informed about nutrition’s potential role in prevention.

Read more:
https://bit.ly/44Riw46

Research has added clarity to the relationship between diet and prostate cancer, including the role of antioxidants, phytochemicals, fatty acids, and processed meats

07/15/2025

ICYMI: Dr. Jacob Meyers and Dr. Jeff Tosoian recently joined the Dr. Geo Podcast to discuss MyProstateScore 2.0 (MPS2), a clinically validated, noninvasive biomarker test for assessing the risk of clinically significant prostate cancer.

Highlights include:

1. How MPS2 complements PSA-based assessments
2. Advantages of its 18-gene urinary biomarker panel
3. Identifying patients who may safely defer biopsy
4. Real-world flexibility and utility of noninvasive urine collection
5. Clinical validation and performance data

Click the links below to listen to both full episodes:
1. Dr. Jacob Meyers – https://bit.ly/4lEFVNl
2. Dr. Jeff Tosoian – https://bit.ly/4ePZRKB

07/14/2025

We’re on the road this July!

Come meet the Lynx Dx team and explore how MyProstateScore 2.0 (MPS2) is advancing prostate cancer risk assessment. No DRE required.

Let’s talk about how MPS2 supports decisions about whether to proceed with biopsy, adds clarity alongside PSA, and fits seamlessly into clinical workflows.

https://bit.ly/44HZL30